Fundraising FoxSanofi Ventures — 2026 Investments
12 investments dated 2026 · listed companies and verified rows first · show all
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)in
Co-investorsJeito CapitalSofinnova PartnersVIVES PartnersApollo Health VenturesSixty Degree Capital
QuantX Bio applies a proprietary computational platform to accelerate the discovery and optimization of drug candidates.
AI & Machine LearningBiotechDeep Tech
Co-investorsOrbiMedCreacion VenturesLilly Asia Ventures
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Board seatChristopher Gagliardi· per SEC Form D
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPProto AxiomSV Health InvestorsTenmileAbingworth+2 more
AgelessRx offers prescription weight management medications delivered through a telehealth platform, including GLP-1 medications (semaglutide, tirzepatide), FDA-approved weight loss drugs (Wegovy, Zepbound), and supportive treatments like metformin and vitamin injections for adults seeking medically-supervised weight loss.
BiotechDigital HealthDirect to ConsumerHealthtechLongevityAnn Arbor, US
Anar Isman(Co-Founder & Chief Executive Officer)inRobert Michael Pejovich(Director of Finance of the Issuer)
Co-investors1/1 Capitalabrdn plcAngelini VenturesFidelity InvestmentsJanus Henderson Investors
Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma.
BiotechHealthtechCollege Park, US
John Clerici(Executive Officer)inAndrew Drechsler(Executive Officer)Brett Giroir(Executive Officer, Director)
BoardNicholas Williams(Director)Moncef Slaoui(Director)Jon Edwards(Director)in
Co-investorsGRA VentureForbionMedicxiPitango
Branchlab offers an AI-driven platform for healthcare marketing that helps teams explore patient, HCP, and caregiver audiences without exposing Protected Health Information, then create, optimize, and activate those audiences across channels.
AI & Machine LearningHealthtechMarketing TechNew York, US
Joshua Walsh(Executive Officer, Director)Christopher Cagle(Executive Officer, Director)
BoardMichael Parkes(Director)inCarrie Williams(Director)inAndrew Bouldin(Director)in
Co-investorsAIX VenturesFCA Venture PartnersMcKesson VenturesNext VenturesNVP CapitalService Provider Capital+2 more
Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
Lei Stanley Qi(Scientific Founder)inAmber Salzman(Executive Officer, Director)inHaorui Zhang(Executive Officer, Director)
BoardAndrew Lam(Director)Anran Li(Director)Jennifer King(Director)
Co-investorsAlly Bridge Groupabrdn plcAngelini VenturesFidelity InvestmentsJanus Henderson Investors
Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's.
BiotechDeep TechHealthtechWaltham, US
Mark Vignola(Chief Financial Officer)inJonathan Violin(President)in
Co-investorsTCG CrossoverWellington ManagementVenrock
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsThe Column GroupSamsara BioCapital
Sensorion is a French clinical-stage biopharmaceutical company founded in 2009 in Montpellier that develops gene-therapy and small-molecule treatments for inner-ear disorders like genetic deafness and tinnitus.
Co-investorsSofinnova PartnersInvusREDMILE
Unspun develops 3D weaving technology and software for apparel and textile manufacturing, enabling fast, automated, and low-waste garment production for brands and manufacturers.
Advanced ManufacturingCleantechClimate TechEmeryville, US
Walden Hoi Ming Lam(Executive Officer, Director)Beth Esponnette(Founder)inKevin Martin(Founder)inARNE ARENS(Executive Officer, Director)inWalden Lam(Founder)
BoardMilo Werner(Director)in
Co-investorsAlumni VenturesCity LightDCVC (Data Collective)E12 Venture Capital, LlcEvolution VenturesFifty Years+10 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.